Hi WAG
No, I didn’t read any negativity re safety and tolerability
No serious adverse events and no dose modifications required
o Most adverse events were mild and not considered related to study drug
o No clinically relevant findings from safety lab tests, or cardiac tests
They were able to proceed to the maximum dose and no serious adverse events were seen. Most adverse events were deemed (by independent assessors) to not relate to the drug.
Ann: Neuren submits IND & first patients complete Phase 2 trials, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.24 |
Change
0.390(3.04%) |
Mkt cap ! $1.652B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.335M | 330.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 271 | $13.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.24 | 365 | 8 |
View Market Depth
| Last trade - 12.20pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |